medigraphic.com
Boletín Médico del Hospital Infantil de México

2009, Number 4

<< Back Next >>

Bol Med Hosp Infant Mex 2009; 66 (4)

Adolescent with AIDS of perinatal transmission

Peña-Alonso YR, Romano-Mazzotti L, Pacheco-Ríos A

Language: Spanish
References: 22
Page: 373-381
PDF size: 368.25 Kb.


Text Extraction

No abstract


REFERENCES

  1. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children (U.S.), United States. Health Resources and Services Administration. National Institutes of Health (U.S.). Guidelines for the use of antiretroviral agents in pediatric HIV infection; 2008 Junio 28; Bethesda, MD: National Institutes of Health; 2008.

  2. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: WHO Press; 2007.

  3. Guia de Manejo Antirretroviral de las Personas con VIH. Mexico, D.F.: Secretaria de Salud; 2007.

  4. American Academy of Pediatrics. Human immunodeficiency virus infection. En: Pickering LK, Baker CJ, Long SS, Mc Millan JA, editores. Red Book: 206 Report of Committe on Infections Diseases. 27th ed. Elk Grove Village, III: American Academy of Pediatrics; 2006. p. 378-401.

  5. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41: 1-19.

  6. Shikuma CM, Valcour VG, Ratto-Kim S, et al. HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages? Clin Infect Dis. 2005; 40: 1846-8.

  7. Kotler D, Wanke C. Management of HIV wasting syndrome: a consensus conference. J Acquir Immune Defic Syndr. 2004; 37 Suppl 5: S261.

  8. Grinspoon S, Mulligan K. Weight loss and wasting in patients infected with human immunodeficiency virus. Clin Infect Dis. 2003; 36: S69-78.

  9. Corcoran C, Grinspoon S. Treatments for wasting in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1999; 340: 1740-50.

  10. Wanke CA, Silva M, Ganda A, et al. Role of acquired immune deficiency syndrome-defining conditions in human immunodeficiency virus-associated wasting. Clin Infect Dis. 2003; 37 Suppl 2: S81-4.

  11. Dworkin MS, Williamson JM. AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr. 2003; 33: 267-73.

  12. UNAIDS. Report on the global HIV/AIDS epidemic 2008: executive summary. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2008.

  13. El VIH/SIDA en México. 2008. Available from: http://www.censida.salud.gob.mx/interior/cifras.html

  14. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008; 300: 51-9.

  15. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet. 2008; 372: 293-9.

  16. Ofori-Mante JA, Kaul A, Rigaud M, et al. Natural history of HIV infected pediatric long-term or slow progressor population after the first decade of life. Pediatr Infect Dis J. 2007; 26: 217-20.

  17. De Angelis DS, Freire WS, Pannuti CS, Succi RC, Machado DM. CCR5 genotypes and progression to HIV disease in perinatally infected children. Braz J Infect Dis. 2007; 11: 196-8.

  18. Mikhail M, Wang B, Saksena NK. Mechanisms involved in non-progressive HIV disease. AIDS Rev. 2003; 5: 230-44.

  19. Ioannidis JP, Contopoulos-Ioannidis DG, Rosenberg PS, et al. Effects of CCR5-delta32 and CCR2-64I alleles on disease progression of perinatally HIV-1-infected children: an international meta-analysis. AIDS. 2003; 17: 1631-8.

  20. Contopoulos-Ioannidis DG, O’Brien TR, Goedert JJ, Rosenberg PS, Ioannidis JP. Effect of CCR5-delta32 heterozygosity on the risk of perinatal HIV-1 infection: a meta-analysis. J Acquir Immune Defic Syndr. 2003; 32: 70-6.

  21. Ometto L, Bertorelle R, Mainardi M, et al. Polymorphisms in the CCR5 promoter region influence disease progression in perinatally human immunodeficiency virus type 1-infected children. J Infect Dis. 2001; 183: 814-8.

  22. Capristo-Gonzalez F, Barragán-Pérez E, Pavía-Ruz N, et al. Manifestaciones neurológicas en pacientes pediátricos y adolescentes mexicanos infectados con VIH/SIDA. Experiencia del Hospital Infantil de México Federico Gómez. Bol Med Hosp Infant Mex. 2008; 65: 6-12.




2020     |     www.medigraphic.com